Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Class A Common Stock, $0.00001 par value per share
-
Shares outstanding
-
4,564,846
-
Total 13F shares
-
251,850,622
-
Share change
-
+43,978,580
-
Total reported value
-
$1,888,683,928
-
Put/Call ratio
-
248%
-
Price per share
-
$7.50
-
Number of holders
-
266
-
Value change
-
+$322,791,585
-
Number of buys
-
174
-
Number of sells
-
91
Institutional Holders of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX) as of Q2 2024
As of 30 Jun 2024,
RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX) was held by
266 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
251,850,622 shares.
The largest 10 holders included
ARK Investment Management LLC, BAILLIE GIFFORD & CO, VANGUARD GROUP INC, BlackRock Inc., RA CAPITAL MANAGEMENT, L.P., Mubadala Investment Co PJSC, Kinnevik AB (publ), Sumitomo Mitsui Trust Holdings, Inc., Nikko Asset Management Americas, Inc., and STATE STREET CORP.
This page lists
264
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.